Company intelligence / Profile preview
KINE SCIENCES
Seoul, Seoul, South Koreakinesciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
KINE-101 completed Phase 1 clinical trial in the US in October 2023 with an excellent safety profile. The first patient was dosed in the Phase 1b/2a dose escalation trial of KINE-101 for CIDP in Korea in September 2024.
- Therapeutic areas
- GastroenterologyImmunologyDermatologyOncologyNeurology
- Modalities
- Small peptide therapeuticsUltra-small size peptidesNanopeptides
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
IMMUNIQUE
Beyond the preview
Go deeper on KINE SCIENCES.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KINE SCIENCES.